Display options
Cite
Gander J, Carrard J, Gallart-Ayala H, et al. Metabolic Impairment in Coronary Artery Disease: Elevated Serum Acylcarnitines Under the Spotlights. Front Cardiovasc Med. 2021;8:792350doi: 10.3389/fcvm.2021.792350.
Gander, J., Carrard, J., Gallart-Ayala, H., Borreggine, R., Teav, T., Infanger, D., Colledge, F., Streese, L., Wagner, J., Klenk, C., Nève, G., Knaier, R., Hanssen, H., Schmidt-Trucksäss, A., & Ivanisevic, J. (2021). Metabolic Impairment in Coronary Artery Disease: Elevated Serum Acylcarnitines Under the Spotlights. Frontiers in cardiovascular medicine, 8792350. https://doi.org/10.3389/fcvm.2021.792350
Gander, Joséphine, et al. "Metabolic Impairment in Coronary Artery Disease: Elevated Serum Acylcarnitines Under the Spotlights." Frontiers in cardiovascular medicine vol. 8 (2021): 792350. doi: https://doi.org/10.3389/fcvm.2021.792350
Gander J, Carrard J, Gallart-Ayala H, Borreggine R, Teav T, Infanger D, Colledge F, Streese L, Wagner J, Klenk C, Nève G, Knaier R, Hanssen H, Schmidt-Trucksäss A, Ivanisevic J. Metabolic Impairment in Coronary Artery Disease: Elevated Serum Acylcarnitines Under the Spotlights. Front Cardiovasc Med. 2021 Dec 16;8:792350. doi: 10.3389/fcvm.2021.792350. eCollection 2021. PMID: 34977199; PMCID: PMC8716394.
Copy Download .nbib Format: NLM
Share it on

Front Cardiovasc Med. 2021 Dec 16;8:792350. doi: 10.3389/fcvm.2021.792350. eCollection 2021.

Metabolic Impairment in Coronary Artery Disease: Elevated Serum Acylcarnitines Under the Spotlights.

Frontiers in cardiovascular medicine

Joséphine Gander, Justin Carrard, Hector Gallart-Ayala, Rébecca Borreggine, Tony Teav, Denis Infanger, Flora Colledge, Lukas Streese, Jonathan Wagner, Christopher Klenk, Gilles Nève, Raphael Knaier, Henner Hanssen, Arno Schmidt-Trucksäss, Julijana Ivanisevic

Affiliations

  1. Division of Sports and Exercise Medicine, Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland.
  2. Metabolomics Platform, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
  3. Division of Sports Science, Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland.

PMID: 34977199 PMCID: PMC8716394 DOI: 10.3389/fcvm.2021.792350

Abstract

Coronary artery disease (CAD) remains the leading cause of death worldwide. Expanding patients' metabolic phenotyping beyond clinical chemistry investigations could lead to earlier recognition of disease onset and better prevention strategies. Additionally, metabolic phenotyping, at the molecular species level, contributes to unravel the roles of metabolites in disease development. In this cross-sectional study, we investigated clinically healthy individuals (

Copyright © 2021 Gander, Carrard, Gallart-Ayala, Borreggine, Teav, Infanger, Colledge, Streese, Wagner, Klenk, Nève, Knaier, Hanssen, Schmidt-Trucksäss and Ivanisevic.

Keywords: acylcarnitine; branched-chain amino acids; carnitine; coronary artery disease; fatty acid oxidation (FAO); metabolomics; mitochondria

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publication Types